The announcement comes just a few months after WHO released its 2024 Bacterial Priority Pathogens List, which highlights the ...

Sanofi and Regeneron’s Dupixent (dupilumab) has been approved by the European Commission (EC) to treat eosinophilic ...

The National Institute for Health and Care Excellence (NICE) has recommended Blueprint Medicines’ Ayvakyt (avapritinib) to ...

Around 86% of clinical trials do not meet patient recruitment goals, ultimately failing to improve patient outcomes and ...

EatMoreFruit, a UK top 10 independent healthcare communication agency, today announced the launch of its European Network to ...

The US Food and Drug Administration (FDA) has approved Journey Medical’s Emrosi (minocycline hydrochloride extended release capsules 40mg) to treat inflammatory lesions of rosacea in adults. Affecting ...

GSK has announced that it will be expanding its immunology pipeline by acquiring a clinical-stage T cell-engager from Chimagen Biosciences in a deal worth $850m. GSK said it plans to develop and ...

Novo Nordisk has shared promising results from a late-stage study of semaglutide in patients with metabolic dysfunction-associated steatohepatitis (MASH), a progressive metabolic disease that affects ...

UCB has announced “encouraging data” from a phase 2a study of its investigational anti-tau antibody bepranemab in Alzheimer’s disease (AD) patients. The TOGETHER study has been evaluating the safety, ...

Johnson & Johnson (J&J) has shared positive results from a late-stage study of its dual-acting IL-23 inhibitor Tremfya (guselkumab) in plaque psoriasis patients. The phase 3b SPECTREM trial has been ...

Susanne Bobadilla from VML Health, joined by a team of 15 medical, digital strategists and client engagement experts from across the company, looks at the top trends coming out of ESMO 2024 and what ...

Principal Medical Writer, Dr Alexandra Loveday explores the importance of storytelling in health communications. Medical facts alone don’t change minds—stories do. Originating from the broader ...